Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-infected individuals in Brazil

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 3, 2008, Pages 399-401

  Diaz, Ricardo Sobhie ^a   Vasconcelos, Lucy ^b   Hayden, Ricardo L ^c   Tenore, Simone ^a   Turcato Jr , Gilberto ^a   Palácios, Ricardo ^a   Sucupira, Maria C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Secretaria Municipal de Saude de Sao Paulo   (Brazil)

^c Santa Casa of Santos Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; VIRUS RNA;

BRAZIL; CLADISTICS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; SEPSIS; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD; VOMITING; ANTIVIRAL RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MUTATION; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VIROLOGY;

BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TIME; TIME FACTORS; TREATMENT OUTCOME;

EID: 42449161096     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815b0d48     Document Type: Letter

References (8)

1. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57-65.
2. Accetturi CA, Pardini R, Novaes Pinto GH, et al. Effects of CCR5 genetic polymorphism and HIV-1 subtype in antiretroviral response in Brazilian HIV-1-infected patients. J Acquir Immune Defic Syndr. 2000;24:399-400.
3. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis. 2005;191:1961-1970.
4. Sucupira MC, Caseiro MM, Alves K, et al. High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS. 2007;21:116-128.
5. De Sa Filho DJ, Sucupira MC, Casiero MM, et al. Identification of two HIV type 1 circulating recombinant forms in Brazil. AIDS Res Hum Retroviruses. 2006;22:1-13.
6. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
7. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther. 2006;11:631-635.
8. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.